Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detecting amyloid-β pathology in subjective cognitive decline using plasma and CSF biomarkers.

EBioMedicine·2026
Same author

An Adnp frameshift variant disrupts Wnt signalling inducing chromatocytoskeletal defects and autism-related behaviour in male mice.

EBioMedicine·2026
Same author

Common pathogenic mechanisms in the hippocampus across neurodegenerative dementias: Alzheimer's disease, Down syndrome, and Parkinson's disease.

NPJ dementia·2026
Same author

Rare ABCA7 mutations in Alzheimer's disease and cerebral amyloid angiopathy pathology.

Neurobiology of aging·2026
Same author

Integrating [<sup>11</sup>C]methylreboxetine PET and MRI to map in vivo norepinephrine transporter distribution: A proof-of-concept study of noradrenergic vulnerability in neurodegeneration.

Nuclear medicine and biology·2025
Same author

Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Jun 20, 2026

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice
06:40

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

No correlation between time-linked plasma and CSF Abeta levels.

Nathalie Le Bastard1, Laetitia Aerts, Judith Leurs

  • 1Laboratory of Neurochemistry and Behavior, Reference Center for Biological Markers of Memory Disorders, University of Antwerp, Antwerp, Belgium.

Neurochemistry International
|August 22, 2009
PubMed
Summary

Plasma and cerebrospinal fluid (CSF) beta-amyloid protein (Abeta) levels do not correlate in Alzheimer's disease (AD) patients or controls. This finding limits the diagnostic use of plasma Abeta as a biomarker for dementia.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of A&#946; and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

Related Experiment Videos

Last Updated: Jun 20, 2026

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice
06:40

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of A&#946; and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

Area of Science:

  • Neuroscience
  • Biochemistry
  • Biomarker Discovery

Background:

  • Plasma beta-amyloid protein (Abeta) isoforms are potential biomarkers for Alzheimer's disease (AD) and dementia.
  • The relationship between plasma and cerebrospinal fluid (CSF) Abeta levels is not well understood.

Purpose of the Study:

  • To investigate correlations between Abeta levels in paired plasma and CSF samples.
  • To assess the diagnostic utility of plasma Abeta as a dementia biomarker.

Main Methods:

  • Analyzed Abeta(1-42) and Abeta(N-42) in plasma and Abeta(1-42) in CSF from 49 AD patients, 47 non-AD dementia patients, 39 MCI patients, and 29 controls.
  • Utilized xMAP technology for plasma assays and ELISA for CSF assays.
  • Assessed CSF/serum albumin index to evaluate blood-brain barrier integrity.

Main Results:

  • No significant correlation was found between plasma Abeta(1-42) and CSF Abeta(1-42) in any group.
  • No correlation was observed between plasma Abeta(N-42) and CSF Abeta(1-42).
  • Plasma Abeta levels did not differ significantly between patient groups and controls.

Conclusions:

  • Plasma and CSF Abeta levels are independent in both dementia patients and controls.
  • The lack of correlation between plasma and CSF Abeta hampers the diagnostic utility of plasma Abeta as a biomarker for dementia.